Clovis Oncology Debt 2025

Clovis Oncology Aktienanalyse

What does Clovis Oncology do?

Clovis Oncology Inc. is a biopharmaceutical company specialized in the development and commercialization of cancer drugs. The company is based in Boulder, Colorado and was founded in 2009. They focus on researching and developing innovative therapies for cancer patients. History: Clovis Oncology was founded by Patrick Mahaffy and his team, who previously worked at Pharmion Corporation and sold the biotech company to Celgene. After the sale of Pharmion, Mahaffy and his colleagues wanted to build something new and started Clovis Oncology. Clovis started its activities in 2009 and initially focused on the development of PARP inhibitors, which can be used for the treatment of breast and ovarian cancer. In 2011, the company conducted Phase I studies with its leading product candidate, Rucaparib. Business model: Clovis Oncology has a business model based on the discovery, development, and commercialization of innovative cancer therapies. The company collaborates closely with academic institutions and other companies to explore and develop new therapies. Clovis has a global network of research and development facilities that allows them to focus on the therapy areas where they are best positioned. Through partnerships and licenses, the company also has access to specialized technologies and expertise in cancer research. Divisions: Clovis Oncology is divided into two divisions: 1. Research and development: Clovis operates an intensive research and development program focused on the discovery and development of new cancer therapies. The focus is on developing PARP inhibitors that offer new treatments for breast and ovarian cancer. The company collaborates closely with academic institutions and other companies to explore and develop new therapies. Clovis has a strong pipeline of products in various stages of clinical development. 2. Commercialization: Clovis also has an experienced marketing team responsible for the marketing and distribution of Rucaparib. Rucaparib is a PARP inhibitor approved for the treatment of breast and ovarian cancer in the United States and several other countries. Products: The main product of Clovis Oncology is Rucaparib, a PARP inhibitor for the treatment of breast and ovarian cancer. The medication was approved by the US Food and Drug Administration (FDA) in December 2016 for use in patients with advanced ovarian cancer. Clovis also has a pipeline of products in various stages of clinical development. The company collaborates closely with academic institutions and other companies to explore and develop new therapies. Summary: Clovis Oncology is a biopharmaceutical company specialized in the development and commercialization of cancer drugs. They have a focus on developing PARP inhibitors and currently offer Rucaparib for the treatment of breast and ovarian cancer. Clovis has a strong pipeline of products in various stages of clinical development and collaborates closely with academic institutions and other companies to advance cancer research. Clovis Oncology ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding Clovis Oncology's Debt Structure

Clovis Oncology's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Clovis Oncology's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Clovis Oncology’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Clovis Oncology’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Clovis Oncology stock

What is the debt of Clovis Oncology this year?

Clovis Oncology has a debt level of 0 USD this year.

What was the debt of Clovis Oncology compared to the previous year?

The debt of Clovis Oncology has increased by 0% compared to the previous year dropped.

What are the consequences of high debt for investors in Clovis Oncology?

High debt can pose a risk for investors of Clovis Oncology, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of Clovis Oncology?

Low debt means that Clovis Oncology has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from Clovis Oncology affect the company?

An increase in debt of Clovis Oncology can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of Clovis Oncology affect the company?

A reduction in debt of Clovis Oncology can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of Clovis Oncology?

Some factors that can influence the debt of Clovis Oncology include investments, acquisitions, operating costs, and revenue development.

Why are the debts of Clovis Oncology so important for investors?

The debts of Clovis Oncology are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can Clovis Oncology take to change the debt?

To change the debt, Clovis Oncology can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does Clovis Oncology pay?

Over the past 12 months, Clovis Oncology paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Clovis Oncology is expected to pay a dividend of 0 USD.

What is the dividend yield of Clovis Oncology?

The current dividend yield of Clovis Oncology is .

When does Clovis Oncology pay dividends?

Clovis Oncology pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Clovis Oncology?

Clovis Oncology paid dividends every year for the past 0 years.

What is the dividend of Clovis Oncology?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Clovis Oncology located?

Clovis Oncology is assigned to the 'Health' sector.

Wann musste ich die Aktien von Clovis Oncology kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Clovis Oncology from 7/5/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/5/2025.

When did Clovis Oncology pay the last dividend?

The last dividend was paid out on 7/5/2025.

What was the dividend of Clovis Oncology in the year 2024?

In the year 2024, Clovis Oncology distributed 0 USD as dividends.

In which currency does Clovis Oncology pay out the dividend?

The dividends of Clovis Oncology are distributed in USD.